Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBridge Biosciences (NBP) Other Accumulated Expenses (2022 - 2025)

NovaBridge Biosciences (NBP) has 4 years of Other Accumulated Expenses data on record, last reported at $9.2 million in Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses rose 8560.38% to $9.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.2 million, a 8560.38% increase, with the full-year FY2025 number at $9.2 million, up 8560.38% from a year prior.
  • Other Accumulated Expenses reached $9.2 million in Q4 2025 per NBP's latest filing, up from $106000.0 in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for NBP hit a ceiling of $9.2 million in Q4 2025 and a floor of $106000.0 in Q4 2024.
  • A 4-year average of $5.8 million and a median of $7.0 million in 2022 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: crashed 97.82% in 2024, then soared 8560.38% in 2025.
  • Tracing NBP's Other Accumulated Expenses over 4 years: stood at $9.1 million in 2022, then tumbled by 46.54% to $4.9 million in 2023, then plummeted by 97.82% to $106000.0 in 2024, then skyrocketed by 8560.38% to $9.2 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for NBP at $9.2 million in Q4 2025, $106000.0 in Q4 2024, and $4.9 million in Q4 2023.